Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.

Increased plasma renin activity (PRA) has been associated with an increased risk of myocardial infarction (MI), whereas angiotensin-converting enzyme (ACE) inhibition appears to reduce the risk of recurrent MI in patients with left ventricular dysfunction. These observations may be partially explained by an interaction between the renin-angiotensin system (RAS) and fibrinolytic system. To test this hypothesis, we examined the effect of salt depletion on tissue-type plasminogen activator (tPA) antigen and plasminogen activator inhibitor-1 (PAI-1) activity and antigen in normotensive subjects in the presence and absence of quinapril (40 mg BID). Under low (10 mmol/d) and high (200 mmol/d) salt conditions there was significant diurnal variation in PAI-1 antigen and activity and tPA antigen. Morning (8 AM through 2 PM) PAI-1 antigen levels were significantly higher during low salt intake compared with high salt intake conditions (ANOVA, F=5.8, P=0.048). PAI-1 antigen correlated with aldosterone (r=0.56, P<10(-7)) during low salt intake. ACE inhibition significantly decreased 24-hour (ANOVA for 24 hours, F=6. 7, P=0.04) and morning (F=24, P=0.002) PAI-1 antigen and PAI-1 activity (F=6.48, P=0.038) but did not alter tPA antigen. Thus, the mean morning PAI-1 antigen concentration was significantly higher during low salt intake than during either high salt intake or low salt intake and concomitant ACE inhibition (22.7+/-4.6 versus 16. 1+/-3.3 and 16.3+/-3.7 ng/mL, respectively; P<0.05). This study provides evidence of a direct functional link between the RAS and fibrinolytic system in humans. The data suggest that ACE inhibition has the potential to reduce the incidence of thrombotic cardiovascular events by blunting the morning peak in PAI-1.

[1]  Duk-KyungKim,et al.  Polymorphism of Angiotensin Converting Enzyme Gene Is Associated With Circulating Levels of Plasminogen Activator Inhibitor-1 , 1997 .

[2]  W. R. Lee,et al.  Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Margaglione,et al.  Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Pfeffer,et al.  Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. , 1997, Circulation.

[5]  M. Alessi,et al.  PAI-1, Obesity, Insulin Resistance and Risk of Cardiovascular Events , 1997, Thrombosis and Haemostasis.

[6]  D. Vaughan,et al.  Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin , 1997, Thrombosis and Haemostasis.

[7]  J. Morrow,et al.  Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. , 1996, The Journal of pharmacology and experimental therapeutics.

[8]  W. Quist,et al.  Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. , 1996, Circulation.

[9]  D. Vaughan,et al.  Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. , 1995, The Journal of clinical investigation.

[10]  J. Breslow,et al.  Effect of fosinopril and vitamin E on LDL peroxidation and atheroclerosis progression in apo E-deficient mice , 1995 .

[11]  P. Kurnik.  Circadian variation in the efficacy of tissue-type plasminogen activator. , 1995, Circulation.

[12]  D. Vaughan,et al.  Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.

[13]  B. Brenner,et al.  Hypertension: Pathophysiology, Diagnosis, and Management , 1994 .

[14]  J. Jespersen,et al.  Regulation of tissue‐type plasminogen activator‐mediated fibrinolysis by plasminogen activator inhibitor type‐1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics , 1994, Coronary artery disease.

[15]  K. Alberti,et al.  Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. , 1994, Journal of the American College of Cardiology.

[16]  D. Goldstein,et al.  Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. , 1994, Journal of chromatography. B, Biomedical applications.

[17]  P. Ridker,et al.  Stimulation of Plasminogen Activator Inhibitor In Vivo by Infusion of Angiotensin II Evidence of a Potential Interaction Between the Renin‐Angiotensin System and Fibrinolytic Function , 1993, Circulation.

[18]  B. Pitt,et al.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions , 1992, The Lancet.

[19]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[20]  D. Loskutoff,et al.  Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Manson,et al.  Baseline Fibrinolytic State and the Risk of Future Venous Thrombosis: A Prospective Study of Endogenous Tissue‐Type Plasminogen Activator and Plasminogen Activator Inhibitor , 1992, Circulation.

[22]  J. Emeis,et al.  On the role of bradykinin in secretion from vascular endothelial cells. , 1992, Agents and actions. Supplements.

[23]  T. Gelehrter,et al.  Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides. , 1992, Molecular endocrinology.

[24]  J. Laragh,et al.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.

[25]  J. Manson,et al.  Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. , 1990, Circulation.

[26]  W. Chandler,et al.  Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. , 1990, Thrombosis research.

[27]  A. Chobanian,et al.  Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. , 1990, Hypertension.

[28]  G. Åberg,et al.  Effects of Captopril on Atherosclerosis in Cynomolgus Monkeys , 1990, Journal of cardiovascular pharmacology.

[29]  T. Gelehrter,et al.  Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells. , 1989, Molecular endocrinology.

[30]  W. Chandler,et al.  Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). , 1989, Circulation.

[31]  A. V. van Zonneveld,et al.  Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[32]  M. Cowan,et al.  American Heart Association. , 2018, P & T : a peer-reviewed journal for formulary management.

[33]  M. Blombäck,et al.  PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.

[34]  C. Kluft,et al.  Plasminogen activator inhibitors. , 1987, Blood.

[35]  R. Skidgel,et al.  The angiotensin I-converting enzyme. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[36]  E. Braunwald,et al.  Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.

[37]  J. Ockene.  Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. , 1985, The American journal of cardiology.

[38]  M. Gilbert,et al.  Tissue plasminogen activator release in vivo in response to vasoactive agents. , 1985, Blood.

[39]  L. Wilkins.  The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: the HDFP experience. The Hypertension Detection and Follow-up Program Cooperative Research Group. , 1984, Circulation.

[40]  J. Verheijen,et al.  Evidence for the Occurrence of a Fast-Acting Inhibitor for Tissue-Type Plasminogen Activator in Human Plasma , 1984, Thrombosis and Haemostasis.

[41]  N. Hollenberg.  The Renin‐Angiotensin System and Sodium Homeostasis , 1984, Journal of cardiovascular pharmacology.

[42]  J. Laragh,et al.  Use of First‐Dose Response or Plasma Renin Activity to Predict the Long‐Term Effect of Captopril: Identification of Triphasic Pattern of Blood Pressure Response , 1980, Journal of cardiovascular pharmacology.

[43]  C. Sussman,et al.  Circulating levels of angiotensin I measured by radioimmunoassay in hypertensive subjects. , 1979, The Journal of laboratory and clinical medicine.

[44]  Skidgel Ra,et al.  The angiotensin I-converting enzyme. , 1977 .

[45]  D. Adams,et al.  Reciprocal influence of salt intake on adrenal glomerulosa and renal vascular responses to angiotensin II in normal man. , 1974, The Journal of clinical investigation.

[46]  J. Brown,et al.  Sensitization of the Adrenal Cortex to Angiotensin II in Sodium‐Deplete Man , 1974, Circulation research.

[47]  J. Sullivan,et al.  Relation of age, diastolic pressure and known duration of hypertension to presence of low renin essential hypertension. , 1973, The American journal of cardiology.

[48]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.